CD8A and neoplasm: Examination of tumor-infiltrating immune cells in recipients treated with anti-PD-1 showed that 6PGD deficiency in MDSCs or 6AN administration enhanced the frequency of tumor-infiltrating CD8+ cells (Fig. 6H, J) and TNF+ CD8+ T cells (Fig. 6I, K).